 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H20Cl2F2N2O2S |
| Molar mass | 497.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Drinabant (INN;AVE-1625) is adrug that acts as aselectiveCB1 receptorantagonist, which was under investigation varyingly bySanofi-Aventis as a treatment forobesity,schizophrenia,Alzheimer's disease,Parkinson's disease, andnicotine dependence.[1][2][3] Though initially studied as a potential treatment for a variety of differentmedical conditions, Sanofi-Aventis eventually narrowed down thetherapeuticindications of the compound to justappetite suppression. Drinabant reachedphase IIbclinical trials for this purpose in the treatment of obesity but was shortly thereafter discontinued,[4] likely due to the observation of severepsychiatricside effects includinganxiety,depression, andthoughts of suicide in patients treated with the now-withdrawnrimonabant, another CB1 antagonist that was also under development by Sanofi-Aventis.[5]
In late 2018, the drug was licensed by Opiant Pharmaceuticals, which intends to develop it for the treatment ofacute cannabinoid overdose (ACO) as an injectable for administration in an emergency department setting. Opiant claims that ACO is most frequently linked to the ingestion ofedibles containing large quantitiesTHC andsynthetic cannabinoids that are more potent and less expensive than marijuana. Edibles, sold as brownies, cookies and candies, pose particular risks for children, who often consume these by accident.[citation needed] There are currently no approved treatments for ACO.
Rimonabant was another cannabinoid receptor antagonist developed for prescription drug use that triggered severe psychiatric side effects and was withdrawn from the market.
